Startup profile for Inductive Bio: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Inductive Bio funding, valuation and investors

Collaborative AI platform accelerating small-molecule optimization via virtual chemistry labs.

Keep track of Inductive Bio

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A

$25M · 2025

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$29M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series a · New York, New York

Investors in latest funding

Lead: Obvious Ventures

Other: Andreessen Horowitz , Lux Capital , Bessemer Venture Partners

Sources: latest funding Last verified: 2026-07-25

Overview

Inductive Bio builds a collaborative AI platform that accelerates small-molecule drug optimization through virtual chemistry labs. The company won consecutive OpenADMET blind benchmarks and runs a pre-competitive data consortium with pharma partners. It raised a $4.3M seed co-led by a16z Bio + Health and Lux Capital (2023), followed by a $25M Series A led by Obvious Ventures (2025).

Why Inductive Bio is interesting

Won consecutive OpenADMET blind benchmarks; pre-competitive data consortium across pharma partners.

Product & use cases

Inductive Bio builds a collaborative AI platform accelerating small-molecule drug optimization through virtual chemistry labs and pre-competitive pharma data consortiums.

  • Virtual chemistry lab for molecule optimization
  • Pre-competitive ADMET benchmarking across pharma partners
  • Collaborative AI-assisted medicinal chemistry

Key facts

  • Seed (2023): $4.3M co-led by a16z Bio + Health (/fund/andreessen-horowitz) and Lux (/fund/lux-capital); Bessemer (/fund/bessemer-venture-partners) participated (PR Newswire)
  • Series A (2025): $25M led by Obvious Ventures; a16z and Lux re-upped (company blog)
  • Won consecutive OpenADMET blind benchmarks for ADMET prediction accuracy

Funding history (newest first)

Series A

2025 $25M

Source: https://www.inductive.bio/blog/series-a

Seed

2023 $4.3M

Source: https://www.prnewswire.com/news-releases/inductive-bio-seed

Investors in our directory

Funds linked from Inductive Bio's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz Lux Capital Bessemer Venture Partners

Competitive landscape

Edge: Won consecutive OpenADMET blind benchmarks — validates predictive accuracy vs. other AI drug discovery tools.

AI drug optimization is crowded; Inductive's OpenADMET benchmark wins provide external validation. Series A ($25M, 2025) funds platform expansion.

  • Schrödinger adjacent

    Physics-based drug discovery; Inductive AI-native optimization.

  • Exscientia direct

    AI drug design; Inductive focuses on optimization benchmarks.

  • Relay Therapeutics adjacent

    Computationally driven discovery; different platform approach.

Notable stories

  • Won consecutive OpenADMET blind benchmarks — external validation of predictive models.
  • Seed co-led by a16z Bio + Health and Lux Capital ($4.3M, 2023).

Industries

Biotech & Life Sciences AI & Machine Learning

FAQs about Inductive Bio

Practical answers founders, operators, and investors typically search for.

Collaborative AI platform accelerating small-molecule optimization via virtual chemistry labs.
a16z (/fund/andreessen-horowitz) and Lux (/fund/lux-capital) co-led seed ($4.3M, 2023). Obvious Ventures led Series A ($25M, 2025). Bessemer (/fund/bessemer-venture-partners) participated in both.
Blind benchmark for ADMET prediction — Inductive won consecutive competitions.
Schrödinger physics-based simulation incumbent; Inductive AI-native optimization with benchmark validation.
Series A — $25M in 2025.
Pharma partners sharing data for model training without competitive molecule exposure — per company materials.
New York, New York.
No — remains private.
Website All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.